Drugs / LPI-1503
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07498751 | Mar → Aug 2025 | — | Luxena Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPI-1503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07498751 ↗ |
| Route | Other | “to be administrated by inhalation” NCT07498751 ↗ |